Stock FENNEC PHARMACEUTICALS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Fennec Pharmaceuticals Inc Other OTC

Equities

CA31447P1009

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Fennec Pharmaceuticals Insider Sold Shares Worth $958,669, According to a Recent SEC Filing
MT
HC Wainwright Raises Fennec Pharmaceuticals Price Target to $18 From $17, Maintains Buy Rating
MT
Fennec Pharmaceuticals Insider Sold Shares Worth $437,451, According to a Recent SEC Filing
MT
Wedbush on Fennec's Q4
MT
Transcript : Fennec Pharmaceuticals Inc., 2023 Earnings Call, Mar 21, 2024
Fennec Pharmaceuticals up 3.2% in US Premarket, Reports Narrower Q4 Loss of $0.10 Per Share
MT
Fennec Pharmaceuticals Brief: Cited Pro forma fourth quarter cash in excess of US$55 million
MT
Fennec Pharmaceuticals Brief: Achieved PEDMARK Full-Year 2023 Net Product Sales of US$21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023
MT
North American Morning Briefing : Investors -2-
DJ
Fennec Pharmaceuticals Brief: Net losses for the fourth quarter and year ended December 31, 2023, of US$2.7 million ($0.10 per share) and $16.0 million ($0.60 per share), respectively
MT
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
GL
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024
GL
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024
AQ
Wedbush on Fennec's Deal for Pedmarqsi in EU
MT
Sector Update: Health Care Stocks Steady Premarket Monday
MT
Sector Update: Health Care
MT
Fennec Pharmaceuticals, Norgine in Exclusive Licensing Agreement to Commercialize Pedmarqsi in Europe, Australia, and NZ
MT
Fennec Pharmaceuticals Brief: Fennec Pharmaceuticals and Norgine Over the Weekend Entered into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FENC Stock
  4. Stock
  5. News Fennec Pharmaceuticals Inc